Hoth Therapeutics, Inc. (NASDAQ:HOTH – Free Report) – Equities research analysts at HC Wainwright issued their Q1 2024 EPS estimates for shares of Hoth Therapeutics in a note issued to investors on Friday, April 5th. HC Wainwright analyst R. Selvaraju forecasts that the company will post earnings of ($0.43) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $4.00 target price on the stock. HC Wainwright also issued estimates for Hoth Therapeutics’ Q2 2024 earnings at ($0.40) EPS, Q3 2024 earnings at ($0.44) EPS, Q4 2024 earnings at ($0.39) EPS, Q1 2025 earnings at ($0.36) EPS, Q2 2025 earnings at ($0.31) EPS, Q3 2025 earnings at ($0.27) EPS, Q4 2025 earnings at ($0.24) EPS and FY2025 earnings at ($1.14) EPS.
Hoth Therapeutics Trading Down 4.3 %
Shares of Hoth Therapeutics stock opened at $1.34 on Monday. The firm has a market capitalization of $5.90 million, a PE ratio of -0.28 and a beta of 0.63. The firm’s 50 day moving average is $1.35 and its 200 day moving average is $1.32. Hoth Therapeutics has a 1 year low of $0.99 and a 1 year high of $4.30.
Institutional Investors Weigh In On Hoth Therapeutics
Hoth Therapeutics Company Profile
Hoth Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19.
Featured Articles
- Five stocks we like better than Hoth Therapeutics
- Dividend Capture Strategy: What You Need to Know
- Will the Shockwave Medical Deal Be the Jolt JNJ Stock Needs?
- How to Invest in the Best Canadian StocksĀ
- The 5 Hottest CEO Stock Purchases So Far This Year
- Market Cap Calculator: How to Calculate Market Cap
- Institutions Think This Consumer Stock Could Break Higher
Receive News & Ratings for Hoth Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hoth Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.